Study supports whooping cough booster shot for adolescentsJune 06, 2005Analysis weighs costs, efficacy, disease severity, and vaccine side effects BOSTON- Despite childhood vaccination rates at all-time highs, pertussis (whooping cough) has re-emerged over the past two decades, especially among adolescents, adults, and young infants. Because of this resurgence, federal health policymakers are considering a national booster vaccination program. An analysis by Harvard Medical School researchers in the June issue of Pediatrics offers support for the adolescent booster, concluding that one-time vaccination at 11 years of age may potentially be cost-effective. The Advisory Committee on Immunization Practices, which advises the Centers for Disease Control and Prevention, meets on June 29-30 and will consider pertussis boosters. Combined acellular pertussis vaccines for adolescents and adults are available in Canada, Australia, and Germany.
Led by Grace Lee, MD, MPH, Harvard Medical School Instructor of Ambulatory Care and Prevention at the Department of Ambulatory Care and Prevention's Center for Child Health Care Studies, the researchers compared six vaccination strategies, ranging from no vaccination after age 6 to adolescent and adult vaccination with 10-year boosters. The computer simulation model used incorporated existing data on pertussis incidence, disease outcomes, vaccine efficacy, vaccine costs, and side effects. (The Department of Ambulatory Care and Prevention is a unique research and teaching collaboration between Harvard Pilgrim Health Care and Harvard Medical School.) The analysis concluded that one-time adolescent vaccination "would result in significant net health benefits and may be reasonably cost-effective," preventing 36 percent of projected pertussis cases at a cost of $20,000 per quality-adjusted life year saved or $1,100 per case prevented. These estimates - less favorable than those for Haemophilius influenza B (Hib) or measles vaccination, but similar to those for pneumococcal vaccination - were highly sensitive to assumptions about disease incidence, vaccine efficacy, side effects, and vaccine costs, the authors write. "In the past, vaccination programs were cost-saving and life-saving," says Lee, who is also an infectious disease specialist at Children's Hospital Boston. "However, newer vaccines are now focused on reducing morbidity, rather than mortality, and we need to carefully weigh the risks and benefits of vaccination. By balancing the costs of a vaccination program and the potential impact of alternative vaccine policies on reducing disease morbidity and improving quality of life, we can optimize decision making regarding vaccine use in the US." Harvard Medical School | |||||||||||||||||||||
|
Related Vaccination Current Events and Vaccination News Articles Researchers develop new self-training gene prediction program for fungi Researchers at the Georgia Institute of Technology have developed a computer program that trains itself to predict genes in the DNA sequences of fungi. Pertussis: Adults can fall severely ill too Pertussis, also known as whooping cough, is not just a childhood disease. Majority of children vaccinated against hepatitis B not at increased risk of MS The majority of children vaccinated against hepatitis B are not at an increased risk of developing multiple sclerosis (MS). Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells A research team, led by investigators at the Department of Surgery at Jefferson Medical College of Thomas Jefferson University and the Kimmel Cancer Center at Jefferson, has achieved a substantial "kill" of pancreatic cancer cells by using nanoparticles to successfully deliver a deadly diphtheria toxin gene. Model highlights benefits and risks of cervical cancer screening methods In an analysis based on a computer model, it appears that comparing the benefits and risks of different cervical cancer prevention approaches may help women and their physicians choose appropriate screening strategies. The prevalence of hepatitis B virus infection in inflammatory bowel disease patients Patients with IBD have high risk of infection by hepatitis viruses B or C because during the course of their disease, they need blood transfusions, and sometimes surgical and endoscopic procedures for diagnosis and treatment. Vaccine against HER2-positive breast cancer offers complete protection in lab Researchers at Wayne State University have tested a breast cancer vaccine they say completely eliminated HER2-positive tumors in mice - even cancers resistant to current anti-HER2 therapy - without any toxicity. Study firmly shows no connection between measles, mumps, rubella (MMR) vaccine and autism In a case-control study, the presence of measles virus RNA was no more likely in children with autism and GI disturbances than in children with only GI disturbances. Higher anaphylaxis rates after HPV vaccination: CMAJ study The estimated rate of anaphylaxis in young women after human papillomavirus (HPV) vaccination was significantly higher - 5 to 20 fold - than that identified in comparable school-based vaccination programs. Most vaccine-allergic children can still be safely vaccinated, Hopkins experts say With close monitoring and a few standard precautions, nearly all children with known or suspected vaccine allergies can be safely immunized, according to a team of vaccine safety experts led by the Johns Hopkins Children's Center. More Vaccination Current Events and Vaccination News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||